908 Devices Inc. (NASDAQ:MASS) Q1 2024 Results Conference Call April 30, 2024 8:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Co-Founder and Chief Executive Officer Joe Griffith - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Jacob Johnson - Stephens Steven Mah - TD Cowen Dan Arias - Stifel Puneet Souda - Leerink Partners Operator Hello, everyone, and welcome to the 908 Devices First Quarter 2024 Financial Results Conference Call. My name is Se ...

908 Devices Inc. (MASS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.81%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.23, delivering a surprise of 14.81%.Over the last four quarters, the company has surpass ...

Exhibit 99.1 908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook First quarter 2024 product and service revenue increased 8% compared to prior year, driven by a 20% increase in handheld revenue Acquired RedWave Technology, expanding forensics product portfolio for point-of-need applications BOSTON – April 30, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial res ...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats. DrugDetect EU and NATO Support and Procurement Agency (NSPA) have both entered into new contracts to deploy the MX908, a handheld high-pressure mass spectrometry (HPMS) device. The MX908 will be used in a variety of sett ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39815 908 DEVICES INC. (Exact name of registrant as specified in its charter) Indicate by check mark whether the r ...

Financial Data and Key Metrics Changes - Revenue for Q4 2023 was $14.4 million, up 23% from $11.6 million in Q4 2022, with total revenue for 2023 at $50.2 million, a 7% increase from $46.9 million in 2022 [4][23][37] - Handheld revenue for 2023 was approximately $37.9 million, representing a 28% year-over-year growth, while desktop revenue was $12 million, a 20% decline compared to the prior year [38][39] - Gross profit for Q4 2023 was $7.3 million, with a gross margin of 51%, consistent with the prior year [32][36] Business Line Data and Key Metrics Changes - Revenue from handheld devices serving the forensics market grew 28% in 2023, significantly offsetting declines in life science instrumentation and bioprocessing markets [5][38] - Desktop revenue for Q4 2023 was $3.2 million, down 2% from the prior year, with a total of five ZipChip interfaces, three REBEL, ten MAVEN, and five MAVERICK device shipments [30][31] - Recurring revenue for the full year was $16.5 million, a 5% increase year-over-year, driven primarily by strong service revenue [33] Market Data and Key Metrics Changes - The company expanded its international presence, with MX908 devices now deployed in 56 countries, up from 45 at the end of 2022 [25] - 25% of MX908 device sales were from outside North America in 2023, compared to 20% in 2022 [25] - The ongoing fentanyl crisis and geopolitical risks are key drivers for demand in handheld devices [10][7] Company Strategy and Development Direction - The company aims to balance operating expense growth with revenue growth, focusing on cash management while pursuing market opportunities [8][24] - Plans to leverage expanded product portfolios to maximize opportunities and strengthen customer engagements, particularly in cell and gene therapy applications [43][66] - The company views 2024 as a transitional year, expecting solid growth from forensics products and overall revenue acceleration as market headwinds subside [41][64] Management's Comments on Operating Environment and Future Outlook - Management expects continued headwinds in the life science instrumentation and bioprocessing markets in the first half of 2024, with a gradual improvement anticipated later in the year [40][64] - The company is confident in returning to robust double-digit growth in 2025, supported by existing cash reserves [41][68] - Management highlighted the importance of strategic partnerships and collaborations to enhance product offerings and market presence [58][92] Other Important Information - The company ended 2023 with zero debt and a healthy cash balance of over $145 million [24][34] - Significant progress was made in partnerships with organizations like Terumo and Cellares to enhance product integration in cell therapy [13][58] Q&A Session Summary Question: Demand outlook for new products in 2024 - Management expressed optimism about the adoption of new products like MAVEN and MAVERICK, noting strong demand for handheld devices driven by geopolitical risks and the fentanyl crisis [46][50] Question: Expectations for desktop product growth - Management indicated that desktop growth is expected to rebound into positive territory in 2024, with gradual improvement anticipated throughout the year [51][75] Question: Differences in instrument usage between partnerships - Management clarified that different instruments are used by partners based on specific unit operations, with MAVEN and MAVERICK serving distinct roles in cell therapy applications [58][87] Question: Composition of leads generated in the second half of 2023 - Management noted that new product launches significantly contributed to increased bookings and leads, particularly for MAVEN and MAVERICK [94] Question: Recurring revenue expectations for 2024 - Management expects recurring revenue to remain around a third of product and service revenue for the full year 2024 [62]

Analysis at the speed of life MARCH 2024 This presentation and the accompanying oral presentation (this "presentation") contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may relate to, but are not limited to, expectations of future results of operations or financial performance of 908 Devices Inc. ("908 Devices," the "Company," "we," "us," or similar te ...

Exhibit 99.1 908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook Fourth quarter 2023 revenue increased 23% compared to prior year, driven by handheld revenue increasing 57% BOSTON – March 5, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2023. "We made solid progress in 2023 towards our ...

908 Devices Inc. (NASDAQ:MASS) Q3 2023 Earnings Call Transcript November 7, 2023 8:30 AM ET Company Participants Kelly Gura - IR Kevin Knopp - Co-Founder, CEO, President & Director Joseph Griffith - CFO & Treasurer Conference Call Participants Steven Mah - TD Cowen Matthew Larew - William Blair Jacob Johnson - Stephens Daniel Arias - Stifel Operator Hello and welcome to today's 908 Devices Third Quarter 2023 Financial Results Conference Call. My name is Jordan and I'll be coordinating your call today. [Oper ...

Analysis for life NOVEMBER 2023 Forward-looking statements are based on information available at the time those statements are made and/or management's good faith beliefs and assumptions as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks and uncertainties include our ability to achieve profitability for any period in the ...